Valneva at the bottom of the SBF 120 with a 4% drop in a risk-averse session

A decline that erases the stock's short-term rebound

Valneva shares fell 3.99% to €2.45 intraday, placing it among the largest decliners on the SBF 120, an index that lost 1.64%. The stock has thus dropped back below its 20-day moving average (€2.49), which it had regained during last Wednesday's rebound, while the quarter remained up 10%.

The 50-day moving average (€2.66) remains 7.7% above the current price, and the 200-day moving average (€2.89) more than 15% above. Over one year, the stock has lost nearly 37%.

The support at €2.33, where the price sits roughly 5% above, is the level to watch. The RSI at 45 is neutral: the day's decline has not yet created an oversold configuration.

A very weak market session, between AI and French debt

Valneva's decline comes in a session where the CAC 40 fell 1.65% and the VIX jumped to 26.74 from 16.61 the previous day. Wall Street experienced its sharpest correction since April 2025 on Thursday, with the Nasdaq down 5.52%, and the sell-off spread to Asia, where the Nikkei lost nearly 6%.

In Paris, the rejection of the first part of the 2027 budget by the National Assembly adds to the picture, while the 10-year French OAT yield remains close to its recent high at 4.75%.

Sanofi, another healthcare stock on the exchange, fell 3.23% although it has gained nearly 16% over one month.

On the company front, first-half 2026 results, published on August 13, confirmed the outlook for 2026, while citing the impact of the geopolitical context on travel among the risks. Regulatory decisions on the Lyme disease vaccine were expected within twelve months of that publication.